Stock A127120 DNA LINK, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials DNA Link, Inc.

Equities

A127120

KR7127120004

Biotechnology & Medical Research

End-of-day quote Korea S.E.
Other stock markets
 06:00:00 2024-05-02 pm EDT 		5-day change 1st Jan Change
2,900 KRW +5.84% Intraday chart for DNA Link, Inc. +16.00% -0.51%
Jan. 25 DNA Link, Inc. announced that it has received KRW 2 billion in funding from Orbitech Co., Ltd. CI
2023 DNA Link, Inc. announced that it has received KRW 5.000000096 billion in funding from Orbitech Co., Ltd. CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 43,595 42,348 157,216 77,460 64,358 54,471
Enterprise Value (EV) 1 41,459 45,594 122,781 55,547 59,660 52,226
P/E ratio -11.6 x -3.2 x -9.54 x -15.2 x -8.18 x -9.01 x
Yield - - - - - -
Capitalization / Revenue 2.93 x 2.72 x 10.3 x 3.37 x 3.79 x 2.48 x
EV / Revenue 2.79 x 2.93 x 8.03 x 2.42 x 3.51 x 2.38 x
EV / EBITDA -34.3 x -7.29 x -31.8 x -13.1 x -17.4 x -19.3 x
EV / FCF -28.2 x -11.8 x 233 x -5.56 x -19.9 x -8.89 x
FCF Yield -3.54% -8.46% 0.43% -18% -5.03% -11.2%
Price to Book 2.22 x 4.38 x 4.06 x 2.36 x 2.31 x 2.07 x
Nbr of stocks (in thousands) 10,738 11,477 16,394 16,394 17,094 18,687
Reference price 2 4,060 3,690 9,590 4,725 3,765 2,915
Announcement Date 3/20/19 3/19/20 3/23/21 3/21/22 3/30/23 3/20/24
1KRW in Million2KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 14,876 15,573 15,286 22,992 16,981 21,949
EBITDA 1 -1,208 -6,257 -3,867 -4,230 -3,438 -2,707
EBIT 1 -2,923 -8,386 -6,004 -5,920 -5,330 -4,235
Operating Margin -19.65% -53.85% -39.28% -25.75% -31.39% -19.29%
Earnings before Tax (EBT) 1 -3,753 -13,137 -13,773 -6,191 -8,077 -5,596
Net income 1 -3,753 -13,118 -13,067 -5,100 -7,782 -5,596
Net margin -25.23% -84.24% -85.48% -22.18% -45.82% -25.5%
EPS 2 -349.5 -1,151 -1,005 -311.1 -460.0 -323.4
Free Cash Flow 1 -1,469 -3,858 527.9 -9,998 -3,002 -5,873
FCF margin -9.87% -24.77% 3.45% -43.49% -17.68% -26.76%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 3/20/19 3/19/20 3/23/21 3/21/22 3/30/23 3/20/24
1KRW in Million2KRW
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - 3,245 - - - -
Net Cash position 1 2,136 - 34,435 21,913 4,697 2,245
Leverage (Debt/EBITDA) - -0.5187 x - - - -
Free Cash Flow 1 -1,469 -3,858 528 -9,998 -3,002 -5,873
ROE (net income / shareholders' equity) -17.4% -89.6% -58.4% -18.3% -27.7% -20.7%
ROA (Net income/ Total Assets) -6.08% -17.2% -9.57% -7.91% -7.88% -6.43%
Assets 1 61,766 76,299 136,579 64,480 98,716 86,970
Book Value Per Share 2 1,826 842.0 2,361 1,999 1,632 1,406
Cash Flow per Share 2 1,100 557.0 2,254 358.0 628.0 351.0
Capex 1 2,515 2,576 1,098 4,020 4,932 2,876
Capex / Sales 16.9% 16.54% 7.18% 17.48% 29.04% 13.1%
Announcement Date 3/20/19 3/19/20 3/23/21 3/21/22 3/30/23 3/20/24
1KRW in Million2KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
DNA LINK, INC. Stock DNA Link, Inc.
-0.51% 39.94M
MODERNA, INC. Stock Moderna, Inc.
+22.81% 46.81B
LONZA GROUP AG Stock Lonza Group AG
+46.62% 41.29B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-1.88% 41.37B
CELLTRION, INC. Stock Celltrion, Inc.
-6.20% 28.87B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+11.33% 26.06B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.00% 19.13B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-1.43% 11.96B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+30.73% 12.39B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-0.48% 12.08B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. A127120 Stock
  4. Financials DNA Link, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW